A meta‐analysis of six studies consisting of 984 human epidermal growth factor receptor 2 (HER2)‐positive BC patients treated with neoadjuvant targeted therapy demonstrated a significant correlation between overweight/obesity and a lower pathological complete response rate.10 Here, ERBB2 is linked to breast cancer.